Page last updated: 2024-09-03

muramylnac-ala-isogln-lys-tripeptide and Osteosarcoma

muramylnac-ala-isogln-lys-tripeptide has been researched along with Osteosarcoma in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bernstein, ML; Betcher, D; Conrad, E; Ferguson, W; Gebhardt, M; Goorin, AM; Grier, H; Harris, MB; Healey, J; Huvos, A; Kleinerman, ES; Krailo, M; Link, M; Meyers, PA; Montebello, J; Nadel, H; Nieder, M; Sato, J; Schwartz, CL; Siegal, G; Weiner, M; Wells, R; Wold, L; Womer, R1
Dubielzig, RR; Fox, LE; Helfand, SC; Keller, ET; Kurzman, ID; MacEwen, EG; Madewell, BR; Rodriguez, CO; Rosenthal, RC; Vail, DM1
Benjamin, R; Bucana, CD; Fidler, IJ; Harris, MB; Jaffe, N; Kleinerman, ES; Krakoff, IH; Raymond, AK1

Trials

3 trial(s) available for muramylnac-ala-isogln-lys-tripeptide and Osteosarcoma

ArticleYear
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Humans; Ifosfamide; Infant; Male; Methotrexate; Osteosarcoma; Prospective Studies

2005
Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:12

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Dog Diseases; Dogs; Double-Blind Method; Drug Carriers; Female; Liposomes; Male; Osteosarcoma

1995
Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid).
    Cancer immunology, immunotherapy : CII, 1992, Volume: 34, Issue:4

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Adolescent; Adult; Chemotherapy, Adjuvant; Female; Humans; Liposomes; Lung Neoplasms; Male; Osteosarcoma; Phosphatidylethanolamines

1992

Other Studies

1 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and Osteosarcoma

ArticleYear
A special grant for special patients from the American Cancer Society.
    Oncology (Williston Park, N.Y.), 1990, Volume: 4, Issue:3

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Bone Neoplasms; Financial Management; Financing, Personal; Fund Raising; Humans; Lung Neoplasms; Osteosarcoma

1990